SUMMARY The narcoleptic syndrome is a life-long and sometimes familial disorder in which there is a disturbance of the rapid eye movement phase of sleep. Patients with periodic sleep in the daytime but no other symptoms seldom develop the narcoleptic syndrome and have a separate unrelated disorder. Twelve patients with the narcoleptic syndrome were treated separately with l(-) amphetamine and d( +) amphetamine. Both drugs abolished narcolepsy, d( +) amphetamine being slightly more potent than l(-) amphetamine. In equipotent doses, unwanted effects of nervousness and insomnia were equal in frequency. No tolerance to either preparation developed during a six month period. Cataplexy was not affected by amphetamine treatment, but was abolished in two patients when clomipramine was given together with either amphetamine.
The treatment of narcolepsy by amphetamines was established by Prinzmetal and Bloomberg in 1935. As a high dosage is often required, toxic effects occur which include insomnia, nervousness, tremor, hypertension, hyperpyrexia and, rarely, acute paranoid psychosis (Connell, 1958) . Amphetamine tolerance and addiction, however, are uncommon (Goodman and Gilman, 1970) . Evidence has been presented which indicates that d( +) amphetamine is twice as potent as the racemic mixture of d( +) and 1(-) amphetamine, suggesting that l(-) amphetamine itself is inactive (Martindale and Westcott, 1967) . L(-) amphetamine has, however, been used successfully by Passouant and his colleagues to treat patients with narcolepsy who have not responded to d( +) amphetamine or in whom this isomer caused dose-limiting unwanted effects Schwab and Passouant, 1964) . Because of this apparent controversy and as the two amphetamine isomers have different biochemical and behavioural effects Taylor and Snyder, 1970) , we have reinvestigated the use of d(+) and l (-) Phase I-I(-) amphetamine and placebo The activity of l(-) amphetamine was compared with placebo during a three week period. All patients took a placebo preparation in the first week. Either If-) amphetamine or placebo was given in the second week (double-blind) and the order of administration was reversed in the third week. The dose of 1(-) amphetamine was 40 mg daily in 10 mg capsules taken at 7. 30, 12, 15.30, and 19.30 urine sample taken during the period of 1(-) amphetamine treatment was analysed for 1(-) and d(+) amphetamine content. The method used was the gas-liquid chromatographic separation of 1(-) and d(+) amphetamine from urine after derivatization with the optically active reagent N-trifluoroacetyl-L-propyl chloride to form a distereoisomeric pair (Beckett and Tester, 1972 Per day (no.) 7 ± 0 45 8 ± 0 47 2.9 ± 0.37* Duration (min)
19 ± 2-9 20 ± 3-0 15 ±4 9 Mean nightly sleep (hr) 7-5 ± 0 37 7-75 ± 0-37 6-5 ± 0-37
Mean values ± 1SEM.
* I(-) amphetamine better than placebo, P < 0 01.
Eleven patients gave a subjective preference for the 1(-) amphetamine period compared with placebo and one patient had no preference. All were taking 1(-) amphetamine during the appropriate period as shown by the gas-liquid chromatographic results. D( +) amphetamine was not detected in the urine samples. The unwanted effects reported are shown in Table 2 . Five patients complained of insomnia while on 1(-) amphetamine. Nervousness, sweating, and palpitations were recorded during both placebo (Table 3) . Cata- CLOMIPRAMINE TREATMENT OF CATAPLEXY Clomipramine abolished cataplexy in the two patients to whom it was given. Both of these previously had occasional sleep paralysis and hypnagogic hallucinations which also responded to this treatment. Clomipramine had no beneficial affect upon narcolepsy and caused slight persistent drowsiness at the commencement of treatment. Blood pressure and pulse rate were not changed by the addition of clomipramine.
DISCUSSION
The narcoleptic syndrome of drowsiness, cataplexy, sleep-paralysis, and hypnagogic hallucinations is not uncommon, but all four symptoms are present in only a third of patients (Wolfenden, 1969) . Double vision or momentary focusing difficulty with ptosis is sometimes the only evidence of cataplexy. The syndrome is a life-long disorder and the prognosis for recovery is poor (Prull, 1963) . Both narcolepsy and cataplexy are occasionally familial; only one of the present patients had an affected relative (Daly and Yoss, 1959; Gelardi and Brown, 1967) . Narcolepsy has been described in patients with disseminated sclerosis and a variety of tumours of the nervous system which are mainly in the periventricular grey matter and neighbouring parts of the diencephalon and mesencephalon (Berg and Hanley, 1963; Tridon et al., 1969) . However, in most of these cataplexy was not present or narcolepsy was an incidental finding. Some patients with narcolepsy also have epilepsy (Symonds, 1954 ), but in those described here, neither epilepsy nor evidence of structural damage to the nervous system was present. The familial occurrence, absence of constant pathological basis, and lifelong nature of the narcoleptic syndrome is consistent with a specific biochemical disorder.
The REM phase of sleep is abnormal in patients with the narcoleptic syndrome (Rechtschaffen et al., 1963) . Night sleep starts with a REM phase. This suggests that the narcoleptic syndrome is unrelated to the condition of excess drowsiness without other symptomatology. The latter patients have normal REM sleep and rarely develop the narcoleptic syndrome (Passouant et al., 1968) . Amphetamines suppress REM sleep (Rechtschaffen and Marron, 1964) , and this may account for their action in narcolepsy, rather than any stimulant effect on the central nervous system; phenelzine which abolishes REM sleep also abolishes narcolepsy (Wyatt et al., 1971) . Despite the action of l(-) amphetamine in reducing the frequency of narcoleptic attacks, the EEG evidence suggests that the drug has no effect on the EEG patterns of narcoleptic diurnal sleep.
The precise relationship between narcolepsy and cataplexy is uncertain, but there is a reduction in muscle tone during sleep and particularly in REM sleep . Stimulation of closely related centres in the animal brain produces either REM sleep or muscular paralysis (Jouvet and Delorme, 1965) .
However, during an attack of cataplexy, the patient is clearly not asleep and the EEG record shows wakefulness . This distinction between narcolepsy and cataplexy is shown also by the action of amphetamine on the first and clomipramine on the second.
Amphetamines affect catecholamine stores in the central nervous system (Carlsson et al., 1965) , but each isomer has a different effect. D(+) amphetamine is 10 times as potent as 1(-) amphetamine in inhibiting the accumulation of noradrenaline in nerve terminals, but both forms are equiactive on dopamine accumulation in selected brain regions . D(+) amphetamine is 10 times as potent as l(-) amphetamine in causing motor hyperactivity in rats, but only one to two times as potent in causing stereotyped behaviour . This agrees with the view that dopamine rather than noradrenaline is associated with stereotyped behaviour, while hypermotility may be related more to noradrenaline (Randrup and Scheel-Kriiger, 1966) . The relative potency of the amphetamine isomers in narcolepsy would thus be consistent with an action on cerebral dopamine rather than on noradrenaline. However, the toxic effects of both amphetamines mimic those of adrenaline, since anxiety, restlessness, palpitations, and tremor occur and not nausea and vomiting. Both drugs control narcolepsy, though, as they may have a different therapeutic index, if toxic symptoms result from d(+) amphetamine, 1(-) amphetamine is worth trial. If cataplexy is disabling, the addition of imipramine or clomipramine is often successful (Akimoto et al., 1960; Passouant et al., 1970) . 
